Prot #D6050C00001: A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and inn Combination with MEDI4736 in Adult Subj

Project: Research project

Project Details

StatusFinished
Effective start/end date11/6/14 → 11/6/17

Funding

  • PRA Health Sciences (Prot #D6050C00001 // Prot #D6050C00001)
  • MedImmune, LLC (Prot #D6050C00001 // Prot #D6050C00001)